Matthew De Silva
COO at Pathos
Chicago, Illinois
Overview
Work Experience
Chief Operating Officer
2021 - Current
Pathos develops an AI-enabled drug discovery platform to reduce the medication development process.
Raised $81,999,992.00 from Lightbank, New Enterprise Associates, Builders VC and Revolution Growth.
Venture Partner
2021
Builders VC is an early stage $250M fund based in San Francisco focused on investing where technology meets new business models to modernize antiquated industries. I focus on healthcare and life sciences opportunities for the team. https://www.builders.vc
Angel Investor & Syndicate Lead
2021
Longtail Bio Ventures invests across all stages of development (with a bias for seed/series a) in companies built to exploit the intersection of biology and technology. Apply here: https://angel.co/s/matt-desilva/12QtZ Over the past 7 years I've been a founder in the emerging space of technology companies that focus on applying tech startup playbooks and approaches to company building to biology. My company, Notable, is in the precision medicine oncology field. There any many other startups advancing in a similar way in digital health, drug discovery, genomic and proteomic diagnostics, and clinical trial design, to name a few. Prior to starting Notable I was a portfolio manager at Peter Thiel's family office/hedge fund Clarium Capital. Many of these companies build platform-based technologies, which can be partnered with other larger collaborators and/or used to build out an internal set of products or pipeline. These create exciting long term opportunities for angel investors, because they can reduce the binary aspect of traditional life science investing. I have built up many relationships over the years in this space, so it made sense to begin investing as an angel and leading syndicates. As a CEO I benefitted from AngelList syndicates in several of our financing rounds, so I've been on the other side of the table from syndicate leads. This allows me to tailor my approach to be as founder-friendly as possible. I also believe in syndicates as a tool to bring in value-added angels to companies, so please feel free to reach out to me anytime to see if there are ways you think you can help a portfolio company!
Advisor and Angel Investor
2020
Endpoint Health is a precision immunology company
Raised $64,000,000.00 from Global Health Investment Fund (GHIF), Wireframe Ventures, Boom Capital Ventures, Mayfield Fund, The Venture Collective, HCX Ventures, Humboldt Fund, Yaya Capital, Growth Capital Ventures and Alix Ventures.
Founder & Executive Chairman
2020 - 2023
Founder and CEO
2014 - 2020
Notable Labs provides personalized drug combination testing service for cancer patients.
Raised $54,840,492.00 from Duro Ventures, Bioverge, Milad Alucozai, Westwood Ventures, Alumni Ventures, Lifeforce Capital, Industry Ventures, First Round Capital and 11.2 Capital.
Portfolio Manager
2012 - 2014
Clarium Capital is a hedge fund that specializes in early stage ventures.
Analyst
2011 - 2012
Intern
2010 - 2010
Education
B.S.
2009 - 2011